The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 14, 2021
Filed:
Nov. 17, 2020
Applicant:
Board of Regents, the University of Texas System, Austin, TX (US);
Inventors:
Everett Stone, Austin, TX (US);
Donjeta Gjuka, Austin, TX (US);
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/60 (2017.01); C12N 9/10 (2006.01); A61K 47/68 (2017.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01); A61K 38/45 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 9/96 (2006.01); C12Q 1/6886 (2018.01); G01N 33/573 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/1077 (2013.01); A61K 38/45 (2013.01); A61K 39/3955 (2013.01); A61K 47/60 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); C12N 9/96 (2013.01); C12Q 1/6886 (2013.01); C12Y 204/02028 (2013.01); G01N 33/573 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract
Methods and compositions related to the engineering of a protein with MTA/ADO-degrading enzyme activity are described. For example, in certain aspects there may be disclosed an MTase capable of degrading MTA/ADO. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer or SCID with an MTase using the disclosed proteins or nucleic acids.